Literature DB >> 9687416

Effects of mutations in GrlA of topoisomerase IV from Staphylococcus aureus on quinolone and coumarin activity.

B Fournier1, D C Hooper.   

Abstract

The grlA genes of Staphylococcus aureus ISP794 (wild type), MT5224c4 (grlA [Phe-80]), MT5224c2 (grlA [Pro-116]), and MT111 (grlA [Glu-116]) were cloned in pSK950, a shuttle vector, and introduced into S. aureus strains derived from strain RN4220. The mutations at position 116 of GrlA (Ala-->Pro or Glu) caused an increase in the level of fluoroquinolone resistance and a decrease in the level of coumarin susceptibility, whereas the mutation at position 80 (Ser-->Phe) caused only an increase in the level of fluoroquinolone resistance. In multicopy alleles, both types of mutations were codominant for fluoroquinolone resistance, and mutations at position 116 were also codominant for coumarin resistance.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9687416      PMCID: PMC105875     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  18 in total

Review 1.  DNA gyrase, topoisomerase IV, and the 4-quinolones.

Authors:  K Drlica; X Zhao
Journal:  Microbiol Mol Biol Rev       Date:  1997-09       Impact factor: 11.056

2.  Crystal structure of the breakage-reunion domain of DNA gyrase.

Authors:  J H Morais Cabral; A P Jackson; C V Smith; N Shikotra; A Maxwell; R C Liddington
Journal:  Nature       Date:  1997-08-28       Impact factor: 49.962

3.  Structure and mechanism of DNA topoisomerase II.

Authors:  J M Berger; S J Gamblin; S C Harrison; J C Wang
Journal:  Nature       Date:  1996-01-18       Impact factor: 49.962

4.  Mechanistic studies of amsacrine-resistant derivatives of DNA topoisomerase II. Implications in resistance to multiple antitumor drugs targeting the enzyme.

Authors:  R A Wasserman; J C Wang
Journal:  J Biol Chem       Date:  1994-08-19       Impact factor: 5.157

5.  Quinolone resistance locus nfxD of Escherichia coli is a mutant allele of the parE gene encoding a subunit of topoisomerase IV.

Authors:  D M Breines; S Ouabdesselam; E Y Ng; J Tankovic; S Shah; C J Soussy; D C Hooper
Journal:  Antimicrob Agents Chemother       Date:  1997-01       Impact factor: 5.191

6.  Alterations in the DNA topoisomerase IV grlA gene responsible for quinolone resistance in Staphylococcus aureus.

Authors:  J Yamagishi; T Kojima; Y Oyamada; K Fujimoto; H Hattori; S Nakamura; M Inoue
Journal:  Antimicrob Agents Chemother       Date:  1996-05       Impact factor: 5.191

7.  Differential behaviors of Staphylococcus aureus and Escherichia coli type II DNA topoisomerases.

Authors:  F Blanche; B Cameron; F X Bernard; L Maton; B Manse; L Ferrero; N Ratet; C Lecoq; A Goniot; D Bisch; J Crouzet
Journal:  Antimicrob Agents Chemother       Date:  1996-12       Impact factor: 5.191

8.  Quinolone resistance mutations in topoisomerase IV: relationship to the flqA locus and genetic evidence that topoisomerase IV is the primary target and DNA gyrase is the secondary target of fluoroquinolones in Staphylococcus aureus.

Authors:  E Y Ng; M Trucksis; D C Hooper
Journal:  Antimicrob Agents Chemother       Date:  1996-08       Impact factor: 5.191

9.  Escherichia coli topoisomerase IV. Purification, characterization, subunit structure, and subunit interactions.

Authors:  H Peng; K J Marians
Journal:  J Biol Chem       Date:  1993-11-15       Impact factor: 5.157

10.  Topoisomerase IV is a target of quinolones in Escherichia coli.

Authors:  A B Khodursky; E L Zechiedrich; N R Cozzarelli
Journal:  Proc Natl Acad Sci U S A       Date:  1995-12-05       Impact factor: 11.205

View more
  11 in total

1.  New mutation in parE in a pneumococcal in vitro mutant resistant to fluoroquinolones.

Authors:  C Janoir; E Varon; M D Kitzis; L Gutmann
Journal:  Antimicrob Agents Chemother       Date:  2001-03       Impact factor: 5.191

2.  DX-619, a novel des-fluoro(6) quinolone manifesting low frequency of selection of resistant Staphylococcus aureus mutants: quinolone resistance beyond modification of type II topoisomerases.

Authors:  Jacob Strahilevitz; Que Chi Truong-Bolduc; David C Hooper
Journal:  Antimicrob Agents Chemother       Date:  2005-12       Impact factor: 5.191

3.  Mechanisms and frequency of resistance to gatifloxacin in comparison to AM-1121 and ciprofloxacin in Staphylococcus aureus.

Authors:  D Ince; D C Hooper
Journal:  Antimicrob Agents Chemother       Date:  2001-10       Impact factor: 5.191

4.  gyrA and gyrB mutations are implicated in cross-resistance to Ciprofloxacin and moxifloxacin in Clostridium difficile.

Authors:  Larbi Dridi; Jacques Tankovic; Béatrice Burghoffer; Frédéric Barbut; Jean-Claude Petit
Journal:  Antimicrob Agents Chemother       Date:  2002-11       Impact factor: 5.191

Review 5.  Mechanisms of fluoroquinolone resistance: an update 1994-1998.

Authors:  L J Piddock
Journal:  Drugs       Date:  1999       Impact factor: 9.546

6.  Selective targeting of topoisomerase IV and DNA gyrase in Staphylococcus aureus: different patterns of quinolone-induced inhibition of DNA synthesis.

Authors:  B Fournier; X Zhao; T Lu; K Drlica; D C Hooper
Journal:  Antimicrob Agents Chemother       Date:  2000-08       Impact factor: 5.191

7.  Mechanisms and frequency of resistance to premafloxacin in Staphylococcus aureus: novel mutations suggest novel drug-target interactions.

Authors:  D Ince; D C Hooper
Journal:  Antimicrob Agents Chemother       Date:  2000-12       Impact factor: 5.191

8.  Activities of different fluoroquinolones against Bacillus anthracis mutants selected in vitro and harboring topoisomerase mutations.

Authors:  Patrick Grohs; Isabelle Podglajen; Laurent Gutmann
Journal:  Antimicrob Agents Chemother       Date:  2004-08       Impact factor: 5.191

9.  Topoisomerase targeting with and resistance to gemifloxacin in Staphylococcus aureus.

Authors:  Dilek Ince; Xiamei Zhang; L Christine Silver; David C Hooper
Journal:  Antimicrob Agents Chemother       Date:  2003-01       Impact factor: 5.191

10.  Quinolone resistance due to reduced target enzyme expression.

Authors:  Dilek Ince; David C Hooper
Journal:  J Bacteriol       Date:  2003-12       Impact factor: 3.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.